EUVIMEDEUVIMED entdecken
Vergleichsstudie

Immunogenicity and safety of the accelerated 2-dose intradermal rabies pre exposure prophylaxis regimen in immunocompetent and immunocompromised pediatric populations: a comparative study

Anurag Agarwal, Charu Singh, Surendra Bahadur Mathur, Vikas Manchanda, Kashvi Agarwal, Mukta Mantan, Amir Maroof Khan

Infection · 2025

DOI: 10.1007/s15010-025-02623-8 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Infection, 2025. Verfasst von Anurag Agarwal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Maulana Azad Medical College & Associated Hospitals, Bahadur Shah Zafar Marg, New Delhi, 110002, India. Hauptthemen laut MEDLINE: Rabies, Rabies Vaccines, Pre-Exposure Prophylaxis, Immunocompromised Host. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Rabies is a fatal zoonotic disease, and India accounts for 35% of global rabies-related deaths. In 2018, the World Health Organization (WHO) revised its guidelines for pre-exposure prophylaxis (PrEP) from a 3-dose to a cost-saving 2-dose intradermal (ID) regimen. This study evaluates the immunogenicity and safety of this regimen in pediatric populations, including children exposed to immunosuppressant therapy. METHODS: This single-center, prospective, comparative follow-up study was conducted at a tertiary care hospital. Participants (5-18 years) were enrolled into two groups: (1) children with no known immunodeficiency (n = 31) and (2) children on immunosuppressant therapy (n = 10). All received Vero cell culture rabies vaccine (RABIVAX-S®) intradermally at two sites on days 0 and 7. Serum anti-rabies virus glycoprotein antibody titres were assessed on days 28, 90, and 180 using an ELISA-based assay. Booster doses were administered to those with insufficient titers (≤ 0.5 EU/ml). RESULTS: By day 28, both groups achieved a 100% seroconversion rate (SCR). Geometric mean titers (GMT) were 2.168 EU/ml and 1.547 EU/ml in the no-known-immunodeficiency and immunosuppressant therapy groups, respectively. At day 90, SCRs were 90% and 70%, with GMTs of 1.358 EU/ml and 0.962 EU/ml, respectively. Booster doses restored titers in all participants with insufficient levels. Pain at the injection site was the only solicited adverse effect. CONCLUSIONS: The 2-dose ID PrEP regimen is immunogenic and safe in pediatric populations, including immunosuppressed children. It offers a cost-effective alternative in rabies-endemic regions, enhancing compliance and accessibility. TRIAL REGISTRATION: Prospectively registered with the Clinical Trials Registry India with Trial Registration No. CTRI/2022/10/046777.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RabiesRabies VaccinesPre-Exposure ProphylaxisImmunocompromised HostHumansChildAdolescentChild, PreschoolMaleFemaleProspective StudiesAntibodies, ViralInjections, IntradermalIndiaFollow-Up StudiesRabies virus

Stichwörter der Autor:innen

ImmunogenicityIntradermal vaccinationPediatric immunosuppressionRabies PrEPSeroconversion

Substanzen

Rabies VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Department of Pediatrics, Maulana Azad Medical College & Associated Hospitals, Bahadur Shah Zafar Marg, New Delhi, 110002, India.
  • Department of Pediatrics, Postgraduate Institute of Child Health, Sector- 30, Gautam Buddha Nagar, Noida, 201303, Uttar Pradesh, India. sbmathur05@gmail.com.
  • Department of Microbiology, Maulana Azad Medical College & Associated Hospitals, Bahadur Shah Zafar Marg, New Delhi, 110002, India.
  • Dr Baba Saheb Ambedkar Medical College & Hospital, Rohini, Delhi, 110085, India.
  • Department of Community Medicine, University College of Medical Sciences and GTB Hospital, Delhi, 110095, India.

Zitieren

APA

Agarwal, A., Singh, C., Mathur, S. B., Manchanda, V., Agarwal, K., Mantan, M., & Khan, A. M. (2025). Immunogenicity and safety of the accelerated 2-dose intradermal rabies pre exposure prophylaxis regimen in immunocompetent and immunocompromised pediatric populations: a comparative study. Infection. https://doi.org/10.1007/s15010-025-02623-8

Vancouver

Agarwal A, Singh C, Mathur SB, Manchanda V, Agarwal K, Mantan M, et al. Immunogenicity and safety of the accelerated 2-dose intradermal rabies pre exposure prophylaxis regimen in immunocompetent and immunocompromised pediatric populations: a comparative study. Infection. 2025. doi:10.1007/s15010-025-02623-8

BibTeX
@article{Agarwal2025,
  author = {Agarwal, Anurag and Singh, Charu and Mathur, Surendra Bahadur and Manchanda, Vikas and Agarwal, Kashvi and Mantan, Mukta and Khan, Amir Maroof},
  title = {Immunogenicity and safety of the accelerated 2-dose intradermal rabies pre exposure prophylaxis regimen in immunocompetent and immunocompromised pediatric populations: a comparative study},
  journal = {Infection},
  year = {2025},
  doi = {10.1007/s15010-025-02623-8}
}
Kostenlos starten →